617,714 Shares in Olema Pharmaceuticals, Inc. $OLMA Acquired by First Turn Management LLC

First Turn Management LLC purchased a new position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 617,714 shares of the company’s stock, valued at approximately $15,443,000. Olema Pharmaceuticals accounts for approximately 1.8% of First Turn Management LLC’s investment portfolio, making the stock its 28th largest position. First Turn Management LLC owned 0.90% of Olema Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of OLMA. EverSource Wealth Advisors LLC lifted its position in shares of Olema Pharmaceuticals by 9,476.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after purchasing an additional 1,232 shares during the period. Torren Management LLC acquired a new position in shares of Olema Pharmaceuticals in the 4th quarter worth approximately $44,000. Russell Investments Group Ltd. acquired a new position in shares of Olema Pharmaceuticals in the 3rd quarter worth approximately $53,000. American Century Companies Inc. acquired a new position in shares of Olema Pharmaceuticals in the 2nd quarter worth approximately $54,000. Finally, Creative Planning acquired a new position in shares of Olema Pharmaceuticals in the 2nd quarter worth approximately $83,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on OLMA. The Goldman Sachs Group dropped their price target on shares of Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. Oppenheimer restated an “outperform” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. Jefferies Financial Group began coverage on shares of Olema Pharmaceuticals in a research report on Thursday, March 19th. They issued a “buy” rating and a $40.00 price target on the stock. Guggenheim dropped their price target on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Finally, Wall Street Zen upgraded shares of Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, April 27th. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Olema Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $44.10.

Olema Pharmaceuticals Stock Performance

NASDAQ:OLMA opened at $9.87 on Friday. The company has a fifty day moving average of $13.96 and a 200-day moving average of $20.57. The firm has a market capitalization of $862.14 million, a P/E ratio of -4.89 and a beta of 1.98. The company has a quick ratio of 10.88, a current ratio of 10.88 and a debt-to-equity ratio of 0.01. Olema Pharmaceuticals, Inc. has a twelve month low of $3.89 and a twelve month high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) earnings per share for the quarter, meeting the consensus estimate of ($0.52). As a group, sell-side analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.16 EPS for the current year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.